H.C. Wainwright lowered the firm’s price target on Karyopharm Therapeutics to $7 from $8 and keeps a Buy rating on the shares. The firm tweaked numbers and is using a higher estimated diluted share count for 2024. It believes investors should still focus on Karyopharm’s pipeline, including combinations for Xpovio in multiple myeloma, myelofibrosis, and the potentially large opportunity in solid tumors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm presents updated exploratory subgroup analyses from SIENDO study
- Karyopharm Shareholders Back Expansion and Elect Directors
- Karyopharm files to sell 45.78M shares of common stock for holders
- Karyopharm Therapeutics Enhances Financial Stability and Liquidity
- Karyopharm still sees 2024 revenue $140M-$160M, consensus $146.52M
Questions or Comments about the article? Write to editor@tipranks.com